Brazil vetoes protectionist clauses in health industrialization law

President Luiz Inácio Lula da Silva signed Law 15.471 on July 20, 2026, establishing a national strategy to develop Brazil's health industrial complex. The legislation directs the state to leverage its massive purchasing power to favor domestic manufacturers of medicines, vaccines, and medical equipment. However, the government simultaneously vetoed three provisions that risked triggering trade disputes, causing drug shortages, or creating bureaucratic gridlock.

The vetoes signal a pragmatic approach to industrial policy. The government struck down a clause allowing new taxes on imported health products, which legal advisors warned would violate Brazil's commitments under the Mercosul trade bloc. Unilateral tariffs could have invited retaliatory measures from Argentina, Uruguay, and Paraguay, potentially harming Brazilian exporters in the agricultural and automotive sectors.

Lawmakers also removed a mandate forcing manufacturers of premium reference drugs to sell in Brazil. Health officials argued this could prompt multinational pharmaceutical companies to abandon the market entirely, creating immediate shortages for the public health system, which serves over 200 million people. A third veto scrapped rigid technology compensation rules, clearing the way for flexible, case-by-case negotiations on knowledge transfer.

For multinational health companies, the resulting legislation offers regulatory certainty. By rejecting sudden tariffs and rigid market access mandates, Brazil has avoided the kind of policy whiplash that disrupts established supply chains. The government can now design partnership models that balance its autonomy goals with the commercial realities required to attract foreign capital.

Nevertheless, the underlying policy remains firmly oriented toward import substitution. Foreign investors face a clear market dynamic: companies that partner with local laboratories or establish domestic manufacturing footprints will likely secure preferential access to the SUS, one of the world's largest single-payer procurement systems. The cleared bureaucratic hurdles also open distinct opportunities for structured joint ventures and research collaborations.

The Brazilian Association of the Pharmaceutical Inputs Industry, ABIQUIFI, welcomed the law as a framework to reduce reliance on imported active pharmaceutical ingredients. The signing ceremony featured Vice President Geraldo Alckmin alongside ministers from health, finance, and industry, underscoring the cross-government priority of the policy. Congress will now review the vetoes, which affect less than 10% of the law's 40 articles, leaving the core industrial strategy intact.